D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 79 Citations 23,090 339 World Ranking 12362 National Ranking 6441

Research.com Recognitions

Awards & Achievements

2002 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is she best known for?

The fields of study Elise C. Kohn is best known for:

  • Cancer
  • Gene
  • Enzyme

In her works, Elise C. Kohn performs multidisciplinary study on Cancer and Pathology. She connects Pathology with Cancer in her research. As part of her studies on Internal medicine, she frequently links adjacent subjects like Toxicity. She regularly ties together related areas like Internal medicine in her Toxicity studies. Elise C. Kohn performs multidisciplinary study in Gene and Proteomics in her work. Elise C. Kohn performs integrative Proteomics and Gene research in her work. In her work, Elise C. Kohn performs multidisciplinary research in Biochemistry and Genetics. In her papers, Elise C. Kohn integrates diverse fields, such as Genetics and Biochemistry. She integrates many fields in her works, including Ovarian cancer and BRCA mutation.

Her most cited work include:

  • Use of proteomic patterns in serum to identify ovarian cancer (2964 citations)
  • The microenvironment of the tumour–host interface (2150 citations)
  • Ovarian cancer (1250 citations)

What are the main themes of her work throughout her whole career to date

Elise C. Kohn conducts interdisciplinary study in the fields of Internal medicine and Gastroenterology through her works. Elise C. Kohn integrates Gastroenterology with Internal medicine in her study. While working in this field, she studies both Cancer and Clinical trial. Elise C. Kohn performs multidisciplinary study in the fields of Clinical trial and Cancer via her papers. In her research, she performs multidisciplinary study on Ovarian cancer and Chemotherapy. She connects Chemotherapy with Ovarian cancer in her research. She connects Oncology with Pathology in her study. She conducts interdisciplinary study in the fields of Pathology and Oncology through her works. Elise C. Kohn connects Biochemistry with Cell biology in her study.

Elise C. Kohn most often published in these fields:

  • Internal medicine (69.95%)
  • Cancer (64.48%)
  • Ovarian cancer (48.09%)

What were the highlights of her more recent work (between 2018-2022)?

  • Cancer (100.00%)
  • Internal medicine (89.47%)
  • Oncology (84.21%)

In recent works Elise C. Kohn was focusing on the following fields of study:

As part of her research on Ovarian cancer, studies on BRCA mutation and Gynecologic cancer are part of the effort. Elise C. Kohn frequently studies issues relating to Ovarian cancer and Gynecologic cancer. Her research on Cancer frequently links to adjacent areas such as Immunotherapy. Her study deals with a combination of Internal medicine and Gynecology. Elise C. Kohn combines Oncology and Intensive care medicine in her research. Elise C. Kohn undertakes multidisciplinary studies into Intensive care medicine and Oncology in her work. Her Clinical trial study frequently draws connections between related disciplines such as Bioinformatics. Her research is interdisciplinary, bridging the disciplines of Clinical trial and Bioinformatics. Borrowing concepts from Disease, Elise C. Kohn weaves in ideas under Gene.

Between 2018 and 2022, her most popular works were:

  • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline (154 citations)
  • PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline (130 citations)
  • A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses (68 citations)

In her most recent research, the most cited works focused on:

  • Cancer
  • Gene
  • Chemotherapy

Her Carcinogenesis study spans across into areas like Cell cycle and Cancer research. Elise C. Kohn integrates many fields, such as Cell cycle and Carcinogenesis, in her works. As part of her studies on Cancer research, she often connects relevant areas like Tumor microenvironment. Her work blends Cancer and Immunology studies together. Immunology connects with themes related to Tumor microenvironment in her study. Elise C. Kohn integrates many fields in her works, including Gene and Bioinformatics. In her work, Elise C. Kohn performs multidisciplinary research in Bioinformatics and Gene. Elise C. Kohn performs multidisciplinary studies into Oncology and Gynecology in her work. In her work, Elise C. Kohn performs multidisciplinary research in Gynecology and Internal medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The microenvironment of the tumour-host interface

Lance A. Liotta;Elise C. Kohn.
Nature (2001)

2917 Citations

Serum Proteomic Patterns for Detection of Prostate Cancer

Emanuel F. Petricoin;David K. Ornstein;Cloud P. Paweletz;Ali Ardekani.
Journal of the National Cancer Institute (2002)

955 Citations

The MAPK pathway across different malignancies: a new perspective.

Mauricio Burotto;Victoria L. Chiou;Jung-Min Lee;Elise C. Kohn.
Cancer (2014)

837 Citations

Molecular Insights into Cancer Invasion: Strategies for Prevention and Intervention

Elise C. Kohn;Lance A. Liotta.
Cancer Research (1995)

725 Citations

Clinical proteomics: translating benchside promise into bedside reality

Emanuel F. Petricoin;Kathryn C. Zoon;Elise C. Kohn;J. Carl Barrett.
Nature Reviews Drug Discovery (2002)

708 Citations

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu;William T. Barry;Michael Birrer;Jung Min Lee.
Lancet Oncology (2014)

556 Citations

Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer

Monica Brown Jones;Henry Krutzsch;Hungjun Shu;Yingming Zhao.
Proteomics (2002)

437 Citations

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

Nilofer S. Azad;Edwin M. Posadas;Virginia E. Kwitkowski;Seth M. Steinberg.
Journal of Clinical Oncology (2008)

373 Citations

Angiogenesis: role of calcium-mediated signal transduction.

Elise C. Kohn;Riccardo Alessandro;Joseph Spoonster;Robert P. Wersto.
Proceedings of the National Academy of Sciences of the United States of America (1995)

363 Citations

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Lee Jm;Ledermann Ja;Kohn Ec.
Annals of Oncology (2014)

327 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Elise C. Kohn

Lance A. Liotta

Lance A. Liotta

George Mason University

Publications: 127

Emanuel F. Petricoin

Emanuel F. Petricoin

George Mason University

Publications: 106

Robert L. Coleman

Robert L. Coleman

The University of Texas MD Anderson Cancer Center

Publications: 46

Ben Davidson

Ben Davidson

Oslo University Hospital

Publications: 41

Virginia Espina

Virginia Espina

George Mason University

Publications: 40

Gordon B. Mills

Gordon B. Mills

Oregon Health & Science University

Publications: 38

Riccardo Alessandro

Riccardo Alessandro

University of Palermo

Publications: 36

Eleftherios P. Diamandis

Eleftherios P. Diamandis

Mount Sinai Hospital

Publications: 36

Ursula A. Matulonis

Ursula A. Matulonis

Harvard University

Publications: 35

Amit M. Oza

Amit M. Oza

Princess Margaret Cancer Centre

Publications: 33

Timothy D. Veenstra

Timothy D. Veenstra

Cedarville University

Publications: 30

Claes G. Tropé

Claes G. Tropé

University of Oslo

Publications: 28

Jonathan A. Ledermann

Jonathan A. Ledermann

University College London

Publications: 28

Kevin R. Coombes

Kevin R. Coombes

The Ohio State University

Publications: 26

William D. Figg

William D. Figg

National Institutes of Health

Publications: 26

Giovanni Scambia

Giovanni Scambia

Catholic University of the Sacred Heart

Publications: 26

Trending Scientists

Shibing Long

Shibing Long

University of Science and Technology of China

David Amouroux

David Amouroux

University of Pau and the Adour Region

Francisco J. Heredia

Francisco J. Heredia

University of Seville

Jack Lewis

Jack Lewis

University of Cambridge

Roscoe Stanyon

Roscoe Stanyon

University of Florence

Jan Tytgat

Jan Tytgat

KU Leuven

Andrzej Ciereszko

Andrzej Ciereszko

Polish Academy of Sciences

Kaisa Granfors

Kaisa Granfors

University of Turku

Karl E. Karlstrom

Karl E. Karlstrom

University of New Mexico

Bradford C. Dickerson

Bradford C. Dickerson

Harvard Medical School

Denis Wakefield

Denis Wakefield

University of New South Wales

Patricia Caspar

Patricia Caspar

National Institute of Allergy and Infectious Diseases

Rinad S. Beidas

Rinad S. Beidas

University of Pennsylvania

Kristine Doney

Kristine Doney

Fred Hutchinson Cancer Research Center

Paul S. Aisen

Paul S. Aisen

University of Southern California

Marijke Frölich

Marijke Frölich

Leiden University Medical Center

Something went wrong. Please try again later.